Molybdenum Disulphide Modified Polylactide for 3D Printed (FDM/FFF) Filaments.

MoS is an additive used to improve the tribological properties of plastics. In this work, it was decided to verify the use of MoS as a modifier of the properties of PLA filaments used in the additive FDM/FFF technique. For this purpose, MoS was introduced into the PLA matrix at concentrations of 0.

Deposition of Biocompatible Polymers by 3D Printing (FDM) on Titanium Alloy.

Nowadays, the replacement of a hip joint is a standard surgical procedure. However, researchers have continuingly been trying to upgrade endoprostheses and make them more similar to natural joints. The use of 3D printing could be helpful in such cases, since 3D-printed elements could mimic the natural lubrication mechanism of the meniscus.

Low-cost, programmable infusion pump with bolus mode for in-vivo imaging.

Syringe pumps are routinely used in biomedical imaging laboratories for delivering contrast agents and either infusing or injecting a precise amount of liquids. Commercial syringe pumps that are developed by specialized companies are expensive and only have standard functions, which often do not meet the requirements of individual experiments. In this paper, we demonstrate an open-source single syringe pump with the possibility of adapting to the needs of a researcher.

Graphite Modified Polylactide (PLA) for 3D Printed (FDM/FFF) Sliding Elements.

With the development of 3D printing technology, there is a need to produce printable materials with improved properties, e.g., sliding properties.

The Influence of Deformation under Tension on Some Mechanical and Tribological Properties of High-Density Polyethylene.

Polymer materials are increasingly being used for sliding machine elements due to their numerous advantages. They are used even where they are deformed and in such a state that they interact frictionally, e.g.

Synthesis of amide and sulfonamide substituted N-aryl 6-aminoquinoxalines as PFKFB3 inhibitors with improved physicochemical properties.

In oncology, the "Warburg effect" describes the elevated production of energy by glycolysis in cancer cells. The ubiquitous and hypoxia-induced 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) plays a noteworthy role in the regulation of glycolysis by producing fructose-2,6-biphosphate (F-2,6-BP), a potent activator of the glycolysis rate-limiting phosphofructokinase PFK-1. Series of amides and sulfonamides derivatives based on a N-aryl 6-aminoquinoxaline scaffold were synthesized and tested for their inhibition of PFKFB3 in vitro in a biochemical assay as well as in HCT116 cells.

Discovery and Structure-Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors.

Energy and biomass production in cancer cells are largely supported by aerobic glycolysis in what is called the Warburg effect. The process is regulated by key enzymes, among which phosphofructokinase PFK-2 plays a significant role by producing fructose-2,6-biphosphate; the most potent activator of the glycolysis rate-limiting step performed by phosphofructokinase PFK-1. Herein, the synthesis, biological evaluation and structure-activity relationship of novel inhibitors of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which is the ubiquitous and hypoxia-induced isoform of PFK-2, are reported.